INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 26, 2026 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025:

• Cash: € 526,751.56
• Number of shares: 58,515
• Number of executions on buy side on semester: 2,332
• Number of executions on sell side on semester: 2,741
• Traded volume on buy side on semester: 550,198 shares for € 2,093,559.19
• Traded volume on sell side on semester: 576,215 shares for € 2,189,327.66

At the last half-year report as of 30 June 2025 the following resources were available in the liquidity account:

• Cash: € 428,212.57
• Number of shares: 84,532
• Number of executions on buy side on semester: 1,642
• Number of executions on sell side on semester: 1,878
• Traded volume on buy side on semester: 267,584 shares for € 744,692.94
• Traded volume on sell side on semester: 296,504 shares for € 819,771.51

When the contract was initially implemented, the following resources were included in the liquidity account:

• Cash: € 163,510.42
• Number of shares: 34,063

	Buy Side				Sell Side
	Number of executions	Number of shares	Traded volume in EUR		Number of executions	Number of shares	Traded volume in EUR
Total	2,332	550,198	2,093,559.19		2,741	576,215	2,189,327.66
07/01/2025	14	2,613	6,846.06		10	1,236	3,275.40
07/02/2025	18	3,372	8,699.76		-	-	-
07/03/2025	9	1,501	3,977.65		49	8,037	21,378.42
07/04/2025	17	2,999	7,917.36		2	500	1,325.00
07/07/2025	21	1,516	4,017.40		19	3,342	8,923.14
07/08/2025	4	837	2,293.38		37	5,720	15,730.00
07/09/2025	10	1,750	4,830.00		21	2,500	6,975.00
07/10/2025	5	778	2,155.06		10	1,001	2,782.78
07/11/2025	8	1,607	4,467.46		16	1,999	5,597.20
07/14/2025	18	2,878	7,885.72		5	550	1,518.00
07/15/2025	3	252	690.48		20	2,500	6,900.00
07/16/2025	7	1,498	4,149.46		13	1,977	5,515.83
07/17/2025	1	250	695.00		10	1,023	2,843.94
07/18/2025	8	1,000	2,760.00		4	240	669.60
07/21/2025	15	2,270	6,197.10		1	250	685.00
07/22/2025	6	1,000	2,750.00		27	3,760	10,377.60
07/23/2025	33	5,730	15,757.50		35	6,450	17,995.50
07/24/2025	8	1,750	4,742.50		-	-	-
07/25/2025	-	-	-		4	1,000	2,780.00
07/28/2025	21	4,750	13,347.50		42	7,753	22,173.58
07/29/2025	2	250	725.00		75	11,154	32,346.60
07/30/2025	27	4,531	12,958.66		10	1,615	4,731.95
07/31/2025	20	3,969	11,192.58		25	4,750	13,585.00
08/01/2025	17	2,750	7,755.00		7	1,251	3,590.37
08/04/2025	11	2,500	6,950.00		5	1,031	2,876.49
08/05/2025	13	1,750	4,935.00		12	1,719	4,864.77
08/06/2025	11	1,984	5,555.20		19	3,539	10,050.76
08/07/2025	21	3,000	8,700.00		22	3,411	9,994.23
08/08/2025	12	2,067	5,932.29		21	2,049	5,962.59
08/11/2025	10	2,000	5,840.00		21	2,250	6,592.50
08/12/2025	2	279	825.84		28	3,750	11,137.50
08/13/2025	22	2,901	8,993.10		66	9,750	30,615.00
08/14/2025	4	750	2,527.50		65	10,999	37,396.60
08/15/2025	18	3,750	12,862.50		14	2,050	7,154.50
08/18/2025	3	750	2,535.00		34	5,700	20,406.00
08/19/2025	16	3,250	12,382.50		67	9,000	34,740.00
08/20/2025	11	2,500	9,650.00		14	3,040	11,825.60
08/21/2025	29	4,108	15,651.48		16	3,460	13,390.20
08/22/2025	14	2,992	11,459.36		10	1,751	6,811.39
08/25/2025	7	1,750	6,772.50		39	6,750	27,067.50
08/26/2025	14	2,750	11,110.00		19	3,250	13,292.50
08/27/2025	-	-	-		75	12,250	54,145.00
08/28/2025	20	4,000	19,320.00		38	7,000	34,440.00
08/29/2025	28	6,250	29,500.00		40	5,750	27,887.50
09/01/2025	36	6,750	31,792.50		10	1,500	7,560.00
09/02/2025	16	3,000	13,260.00		10	2,250	10,125.00
09/03/2025	-	-	-		27	5,000	23,400.00
09/04/2025	34	13,000	58,760.00		-	-	-
09/05/2025	6	3,955	17,599.75		2	2,000	9,000.00
09/08/2025	27	12,000	52,320.00		7	10,000	44,000.00
09/09/2025	1	2,000	8,900.00		8	10,000	45,500.00
09/10/2025	-	-	-		3	4,000	18,600.00
09/11/2025	-	-	-		3	1,000	4,750.00
09/12/2025	4	750	3,487.50		-	-	-
09/15/2025	3	2,500	11,300.00		2	250	1,195.00
09/16/2025	4	3,500	15,575.00		2	1,000	4,500.00
09/17/2025	6	7,000	30,170.00		5	4,000	17,360.00
09/18/2025	-	-	-		12	3,000	13,560.00
09/19/2025	-	-	-		4	2,000	9,240.00
09/22/2025	16	2,345	10,904.25		18	3,250	15,307.50
09/23/2025	29	5,750	27,025.00		32	6,500	30,810.00
09/24/2025	30	5,278	24,912.16		16	3,500	16,765.00
09/25/2025	-	-	-		34	6,955	34,427.25
09/26/2025	31	6,750	33,075.00		33	6,250	31,000.00
09/29/2025	40	9,500	46,930.00		35	7,000	35,280.00
09/30/2025	39	8,000	38,560.00		20	3,750	18,337.50
10/01/2025	14	2,751	13,554.95		33	6,250	31,270.00
10/02/2025	12	2,750	13,970.00		38	7,335	37,921.95
10/03/2025	37	8,000	42,640.00		41	6,250	33,625.00
10/06/2025	47	9,250	47,452.50		13	1,500	7,755.00
10/07/2025	40	8,249	41,162.51		24	3,750	19,387.50
10/08/2025	47	8,722	40,470.08		20	3,047	14,503.72
10/09/2025	49	10,900	46,216.00		35	6,000	25,620.00
10/10/2025	41	9,250	37,185.00		27	4,750	19,380.00
10/13/2025	52	9,900	38,412.00		12	2,750	10,917.50
10/14/2025	30	6,500	23,855.00		56	12,000	46,200.00
10/15/2025	37	8,000	30,880.00		13	3,000	11,760.00
10/16/2025	27	5,750	20,757.50		26	5,069	18,856.68
10/17/2025	30	6,250	21,625.00		21	4,000	13,960.00
10/20/2025	30	6,750	22,545.00		13	3,250	10,985.00
10/21/2025	15	3,500	11,550.00		16	2,750	9,212.50
10/22/2025	29	6,600	21,054.00		9	2,000	6,400.00
10/23/2025	23	4,899	15,039.93		19	4,500	13,950.00
10/24/2025	18	4,000	12,280.00		17	3,474	10,977.84
10/27/2025	13	3,000	9,210.00		44	7,500	23,325.00
10/28/2025	13	3,250	10,562.50		72	13,526	44,500.54
10/29/2025	52	12,000	39,600.00		95	20,181	74,669.70
10/30/2025	47	8,755	30,467.40		3	750	2,625.00
10/31/2025	5	1,250	4,500.00		33	6,750	24,435.00
11/03/2025	35	7,295	26,043.15		26	4,574	16,740.84
11/04/2025	21	3,005	10,547.55		34	7,177	25,837.20
11/05/2025	26	4,606	16,489.48		9	2,250	8,190.00
11/06/2025	12	2,050	7,646.50		39	7,500	28,350.00
11/07/2025	24	5,344	19,398.72		5	1,250	4,650.00
11/10/2025	39	8,495	29,052.90		4	750	2,685.00
11/11/2025	12	2,250	7,312.50		-	-	-
11/12/2025	6	1,500	5,040.00		26	4,500	15,210.00
11/13/2025	9	2,250	7,245.00		3	750	2,430.00
11/14/2025	9	2,250	7,177.50		12	2,500	8,325.00
11/17/2025	10	2,500	8,575.00		46	8,000	28,080.00
11/18/2025	22	3,750	12,975.00		11	1,500	5,235.00
11/19/2025	14	3,000	10,410.00		14	3,500	12,285.00
11/20/2025	17	2,750	9,570.00		18	4,250	15,130.00
11/21/2025	28	4,895	17,132.50		8	2,000	7,100.00
11/24/2025	13	2,800	9,660.00		30	4,000	14,000.00
11/25/2025	15	3,307	12,037.48		51	10,000	36,900.00
11/26/2025	36	12,000	45,960.00		34	11,520	45,388.80
11/27/2025	17	6,500	24,245.00		30	9,000	34,110.00
11/28/2025	21	4,443	16,261.38		1	500	1,850.00
12/01/2025	6	2,000	7,240.00		4	1,000	3,690.00
12/02/2025	28	12,500	46,750.00		17	7,500	28,725.00
12/03/2025	48	14,255	49,607.40		-	-	-
12/04/2025	16	5,500	19,140.00		14	5,000	17,550.00
12/05/2025	22	4,500	15,705.00		7	2,506	8,821.12
12/08/2025	9	2,500	8,700.00		21	6,912	24,192.00
12/09/2025	12	5,000	17,750.00		25	8,082	29,014.38
12/10/2025	23	6,206	22,713.96		31	11,060	41,475.00
12/11/2025	18	7,000	26,180.00		16	5,000	19,000.00
12/12/2025	5	2,000	7,520.00		1	80	308.80
12/15/2025	26	9,000	33,750.00		15	5,500	20,900.00
12/16/2025	23	9,294	33,830.16		21	8,001	29,523.69
12/17/2025	13	6,000	22,620.00		29	9,359	35,844.97
12/18/2025	18	8,000	30,320.00		17	6,943	27,216.56
12/19/2025	22	9,500	34,675.00		13	5,000	18,450.00
12/22/2025	21	6,500	23,335.00		22	8,000	29,280.00
12/23/2025	22	7,500	28,800.00		29	10,494	40,821.66
12/24/2025	12	4,353	16,280.22		10	4,000	15,160.00
12/29/2025	4	64	239.36		13	3,563	13,681.92
12/30/2025	5	1,000	3,880.00		3	1,500	5,910.00
12/31/2025	5	1,000	3,870.00		2	500	1,960.00

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com

Contacts

Inventiva Pascaline Clerc, PhD EVP, External and Corporate Affairs [e-mail] [phone]

ICR Healthcare Alexis Feinberg Media Relations [e-mail] [phone]

ICR Healthcare Patricia L. Bank Investor Relations [e-mail] [phone]

Attachment

• Inventiva - PR Liquidity contract - H2 2025 - 01 21 2026